Supplementary Materials

The PDF file includes:

  • Fig. S1. Quantitation of kinase abundance in HGSOC tumors using MIB-MS and s-SILAC.
  • Fig. S2. Characterization of MRCKA in HGSOC tumors and HGSOC cell lines.
  • Fig. S3. Exploring MRCKA knockdown in HGSOC cells using MIB-MS and phosphoproteomics.
  • Fig. S4. MRCKA promotes focal adhesion signaling in HGSOC cells.
  • Fig. S5. Evaluation of MRCKA kinase inhibitors in HGSOC cells.
  • Fig. S6. Characterization of proliferation, migration, apoptosis, and spheroid formation in BDP9066-treated HGSOC cells.
  • Legends for data files S1 to S10

[Download PDF]

Other Supplementary Material for this manuscript includes the following:

  • Data file S1 (Microsoft Excel format). Raw and processed s-SILAC ratios from MIB-MS profiling of sections from a single HGSOC tumor tissue.
  • Data file S2 (Microsoft Excel format). Characteristics of HGSOC primary and PDX tumors used in MIB-MS studies.
  • Data file S3 (Microsoft Excel format). Raw and processed s-SILAC ratios from MIB-MS profiling of HGSOC primary and PDX tumors.
  • Data file S4 (Microsoft Excel format). Prevalent MIB-MS kinome signature among HGSOC primary and PDX tumors.
  • Data file S5 (Microsoft Excel format). IHC analysis of MRCKA protein levels in HGSOC tumor sections, normal fallopian tube, and ovarian surface epithelial tissues.
  • Data file S6 (Microsoft Excel format). Raw and processed s-SILAC ratios from MIB-MS profiling of MRCKA knockdown in HGSOC cells.
  • Data file S7 (Microsoft Excel format). Raw and processed s-SILAC ratios from phosphoproteomics analysis of MRCKA knockdown in HGSOC cells.
  • Data file S8 (Microsoft Excel format). In vitro kinase inhibitor profiling report for BDP5290 and BDP9066.
  • Data file S9 (Microsoft Excel format). Raw and processed SILAC ratios from MIB-MS profiling of OVSAHO cells treated with BDP9066 or A-674563.
  • Data file S10 (Microsoft Excel format). Reagents used in the study, including small molecules, siRNAs, and antibodies.